GlassScriptPhysician profile
Donald J Tynes
NPI 1609851153
$6,374.04
in general payments reported to CMS, 2019-2025
36 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $689 · 2021: $1,071 · 2022: $749 · 2023: $838 · 2024: $973 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,940 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.42 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,030.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $908.56 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $585.11 | 2020-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $467.69 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $373.50 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $349.54 | 2020-2024 | Verquvo |
| Eisai INC. | $295.15 | 2024-2025 | |
| Lilly USA, LLC | $284.41 | 2020-2025 | Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $208.22 | 2021-2025 | Caplyta |
| Glaxosmithkline, LLC. | $198.83 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Allergan, INC. | $195.90 | 2019-2020 | |
| Amgen INC. | $157.91 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $115.37 | 2019-2023 | |
| Genentech USA, INC. | $111.30 | 2019-2021 | |
| Abbott Laboratories | $106.65 | 2024-2025 | Freestyle Libre 3 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $97.23 | 2023-2025 | Rexulti |
| Dexcom, INC. | $94.25 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $91.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $86.36 | 2024 | Austedo Xr |
| Mylan Specialty L.P. | $82.94 | 2019-2021 | |
| Cequr Corporation | $72.20 | 2025 | Cequr Simplicity |
| Abbvie INC. | $67.62 | 2021-2024 | |
| Exact Sciences Corporation | $48.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Global Blood Therapeutics, INC. | $45.24 | 2022 | |
| Corcept Therapeutics | $45.13 | 2023 | Korlym |
| Neurocrine Biosciences, INC. | $40.15 | 2023 | Ingrezza |
| Boston Scientific Corporation | $38.88 | 2025 | Watchman Flx |
| Scpharmaceuticals INC. | $36.97 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.90 | 2021 | |
| Daiichi Sankyo INC. | $18.96 | 2024 | Injectafer |
| Abiomed | $18.07 | 2025 | |
| Alkermes, INC. | $17.15 | 2024 | Vivitrol |
| Amarin Pharma, INC. | $16.43 | 2020 | |
| Vyera Pharmaceuticals, LLC | $15.56 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.52 | 2019 | |
| Axsome Therapeutics, INC. | $15.43 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Tynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.